TokenPost·
Veradermics' VDPHL01 Meets All Endpoints in Phase 3 Study '304' Part A
536 men
trial enrollment
The six-month, placebo-controlled portion of the trial enrolled 536 men with mild-to-moderate pattern hair loss.
More news
- TokenPostSanDisk Shares Rise 7.23% as Storage Chip Stocks Gain on Oct. 19
- TokenPostNEAR Advances Automated Proof Generation to Lower Verification Costs
- TokenPostEuronet, Fireblocks Expand Partnership Into Stablecoin Card Issuing
- CryptoSlateStrategy’s discretionary cash falls 72% as buyback authorization rises to $3 billion
- TokenPostUber Wins Ruling That London Taxi Claims Were Filed Too Late
- NewsBTCGerman Savings Banks Begin Crypto Trading Rollout Inside Sparkassen App